Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Neoplasms
Interventions: BIOLOGICAL: Pembrolizumab|DRUG: Nab-paclitaxel|DRUG: Anthracycline (doxorubicin)|DRUG: Cyclophosphamide|DRUG: Carboplatin|DRUG: Paclitaxel
Sponsor: Merck Sharp & Dohme LLC